CTLA4 and neoplasm: Immune checkpoint inhibitor (ICI) therapies, including anti-PD1, anti-PD-L1, and anti-CTLA-4 therapies, have played a role in enhancing the activities of effective T cells and inhibiting the immunosuppression in the tumor microenvironment [1, 2].